Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]
about
Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759].Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the InterdisciplinaComparison of Venae Sectio vs. modified Seldinger Technique for totally implantable access ports; Portas-trial [ISRCTN:52368201]Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancerHypoxia and angiogenesis in pancreatic cancer.Update on pancreatic cancer and alcohol-associated risk.Medical treatment of pancreatic cancer.Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancerInfluence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors.Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer.Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine
P2860
Q27332109-5D51DD83-158A-427F-92C8-C9CBCCF5A3A9Q33243003-2794CA76-DECB-4740-B655-963620E19DE6Q33276956-67A6A126-181F-4E00-A700-9B469343E7DCQ34997171-A756A0FA-EDDB-43A5-91B0-E7156427AFCAQ36014277-540986D7-22B9-4556-BBE5-D6991B47EA1AQ36572752-06C0988E-C418-49EF-A82A-AAE65DC20B54Q36588233-BF8C26CD-1D0E-4E2E-A5FA-06AB809F421CQ36788494-75D46081-6669-4938-BBDA-E5489AF7DE04Q36859193-E18F85AB-03B5-4B43-A17C-4808DBB31FB7Q37684031-204FE194-7268-449E-A046-E1196FA4BA8CQ38152980-0506A694-7E2B-407B-9437-857D27071CF2Q38413842-05085498-4CC1-40BD-BBFD-45CD539CBC09Q55004955-7B32E4D0-D499-44EB-9613-05333F3988A9Q56524291-2B139B7F-2689-4365-AC02-E8428BA8F0CF
P2860
Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@ast
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@en
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@nl
type
label
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@ast
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@en
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@nl
prefLabel
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@ast
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@en
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@nl
P2093
P2860
P356
P1433
P1476
Phase III trial of postoperati ...... tudy protocol [ISRCTN62866759]
@en
P2093
H Goldschmidt
H P Knaebel
H Schmitz-Winnenthal
K Hoffmann
R Krempien
P2860
P2888
P356
10.1186/1471-2407-5-37
P407
P577
2005-04-12T00:00:00Z
P5875
P6179
1027053207